ArticleScientific reports2025
Pan-cancer landscape of ITGAV and its potential role in gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-translational modifications of integrins: molecular mechanisms and pathological implications.Cellular and molecular life sciences : CMLS · 2026Review
- The Double-Edged Sword of Genomic DNA Methylation: Orchestrating Gastric Carcinogenesis and Shaping Precision Oncology.Oncology research · 2026Review
- Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions.Molecular biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Integrin subunit alpha V (ITGAV), a subunit of the integrin receptor, is involved in many types of cancers. In order to explore the potential mechanisms of ITGAV in cancers, we carried out a comprehensive pan-cancer analysis using public database. In this study, ITGAV expression in different cancers and the relationship between ITGAV and clinic-pathological features, prognosis, genetic alteration, epigenetic modification, and tumor immune microenvironment were systemically analyzed. Gene enrichment analysis was performed to explore potential functions of ITGAV in gastric cancer (GC). GC tissue microarrays and in vitro cell experiments were used to verify the prediction results in GC. The results revealed that ITGAV was variably expression in different cancers, and ITGAV had a certain prognostic and diagnostic value in most cancers, including GC. ITGAV expression was found to be related to genetic alteration, DNA methylation, immune checkpoint gene, and immune cell infiltration in multiple cancers. Functional analyses revealed that ITGAV was involved in the regulation of EMC remodeling, ferroptosis, and cuproptosis in GC. In vitro experiments verified that ITGAV was correlated with GC cell proliferation, apoptosis, migration, and invasion. Our study demonstrated that ITGAV can be used as an effective prognostic and immunological biomarker for multiple cancers. ITGAV can promote GC malignant progression and could serve as a potential therapeutic target for GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.